Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors

10 Mar 2020

Abstract excerpt

Alterations in the transcriptional factor c-MYC could be involved in the anti-EGFR resistance in metastatic colorectal cancer (mCRC). The c-MYC expression was evaluated in 121 RAS and BRAF wild-type mCRC before treatment with anti-EGFR+Folfiri therapy and in 33 subsequent metastases collected during target therapy (TT) or in TT resistance phase. We analyzed the expression and the functional role of some c-MYC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32164324
DOI: 10.3390/cancers12030638

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR InhibitorsPMID 32164324Read ↗

Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal CancerSemantic proximity Read ↗

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitorsSemantic proximity Read ↗

Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level.Semantic proximity Read ↗

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.Semantic proximity Read ↗

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAFSemantic proximity Read ↗

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.Semantic proximity Read ↗

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Semantic proximity Read ↗

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?Semantic proximity Read ↗

[Prediction of EGFR blockade responses in metastatic colorectal carcinoma].Semantic proximity Read ↗

MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumorsSemantic proximity Read ↗

Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureSemantic proximity Read ↗

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.